Skip to main content

Head and Neck Surgery

1
Pipeline Programs
1
Companies
5
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Alume Biosciences
Alume BiosciencesCA - San Diego
1 program
1
BevonesceinPhase 35 trials
Active Trials
NCT07631650Recruiting40Est. Aug 2027
NCT06662097Completed27Est. Jan 2026
NCT06227585Completed155Est. Jan 2026
+2 more trials

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
Alume BiosciencesBevonescein
Alume BiosciencesBevonescein
Alume BiosciencesBevonescein
Alume BiosciencesBevonescein
Alume BiosciencesBevonescein

Clinical Trials (5)

Total enrollment: 403 patients across 5 trials

NCT05377554Alume BiosciencesBevonescein

Bevonescein for Intra-Operative Nerve Visualization in Head and Neck Surgery

Start: Apr 2022Est. completion: Nov 2025154 patients
Phase 3Completed
NCT06227585Alume BiosciencesBevonescein

Feasibility and Efficacy Study for Bevonescein-Assisted Nerve Visualization in Head & Neck Surgery

Start: Nov 2023Est. completion: Jan 2026155 patients
Phase 2/3Completed
NCT07631650Alume BiosciencesBevonescein

Bevonescein for Improved Intraoperative Nerve Visualization to Improve Voice Outcomes in Thyroidectomy Patients

Start: Oct 2026Est. completion: Aug 202740 patients
Phase 2Recruiting
NCT06662097Alume BiosciencesBevonescein

A Study of Bevonescein in Patients Undergoing Abdominopelvic Surgery

Start: Oct 2024Est. completion: Jan 202627 patients
Phase 2Completed
NCT04420689Alume BiosciencesBevonescein

Bevonescein to Highlight Nerves in Patients Undergoing Head & Neck Surgery

Start: Jun 2020Est. completion: Feb 202227 patients
Phase 1/2Completed

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs, potential near-term approvals
1 actively recruiting trials targeting 403 patients
1 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.